Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S. Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S. , excluding rights to zuranolone in Japan , Taiwan and South Korea Sage
View HTML
Toggle Summary Sage Therapeutics Announces Third Quarter 2020 Financial Results and Highlights Pipeline and Business Progress
Ongoing zuranolone Phase 3 pivotal trials in major depression and postpartum depression progressing well; expect to initiate dosing in CORAL Study in 4Q 2020 Continued execution across brain health franchises highlighted during 2 nd annual FutureCast event First patient dosed in PARADIGM Study
View HTML
Toggle Summary Sage Therapeutics to Present at Upcoming November Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Sage Therapeutics Announces Chief Executive Jeff Jonas to Undergo Scheduled Medical Procedure
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 22, 2020-- Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that Jeff Jonas , M.D.,
View HTML
Toggle Summary Sage Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 19, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD
Zuranolone was generally well-tolerated at the 30 mg dose and by the initial patients treated with the 50 mg dose with an adverse event profile consistent with that seen in earlier trials Nearly half of trial participants with positive response to initial 14-day course of zuranolone 30 mg did not
View HTML
Toggle Summary Sage Therapeutics Appoints Barry Greene to Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the addition of Barry Greene
View HTML
Toggle Summary Sage Therapeutics’ FutureCast to Provide Update on Pipeline Progression and Additional Insights into Potential of Brain Health Franchises
Thinking differently about thinking – Development plans for SAGE-718 focused on executive function across multiple indications Early learnings from studies of other compounds created multi-faceted insights for SAGE-324 program in essential tremor Interview with investigator from SHORELINE study
View HTML
Toggle Summary Sage Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Sage Therapeutics to Host Sage FutureCast Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 20, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it will host Sage
View HTML